Skip to main content
. 2015 Dec 13;2016:1031794. doi: 10.1155/2016/1031794

Table 2.

Pairwise comparisons of efficacy or safety in stem cells-treated patients compared with patients receiving standard therapy.

Groups versus control# LVEF MACE
Number of studies Number of patients I 2 MD (95% CI) Number of studies Number of patients I 2 OR (95% CI)
6 months
1~7 days 23 862/673 71.8 2.57 (1.21~3.94) 16 768/571 0.0 0.51 (0.31~0.82)
1~3 days 6 142/127 36.2 1.26 (−0.66~3.18) 4 143/104 0.0 1.03 (0.30~3.47)
4~7 days 18 881/674 72.3 2.85 (1.61~4.09) 12 625/467 0.0 0.44 (0.26~0.76)
8~14 days 3 34/30 0.0 −0.84 (−4.31~2.64) 0 0
15~30 days 5 187/169 87.1 3.27 (−1.94~8.48) 4 167/140 0.0 1.79 (0.66~4.82)
Total 30 1083/872 73.6 2.53 (1.25~3.82) 19$ 935/711 0.0 0.66 (0.43~1.01)
12 months
1~7 days 10 311/240 50.0 4.34 (2.98~5.69) 9 342/296 12.7 0.31 (0.18~0.55)
1~3 days
4~7 days 10 311/240 50.0 4.34 (2.98~5.69) 9 342/296 12.7 0.31 (0.18~0.55)
8~14 days 2 10/10 0.0 2.33 (−3.95~8.62) 4 42/35 0.0 0.65 (0.15~2.84)
15~30 days 1 19/20 1.30 (−3.09~5.69) 1 21/21 2.11 (0.18~25.17)
Total 13 340/270 42.6 4.09 (2.83~5.34) 14 405/352 0.0 0.45 (0.27~0.76)

One study had arms belonging to 1~3 days' group and another one belonging to 8~14 days' group; $one study had arms belonging to 8~14 days' group and another one belonging to 15~30 days' group. #Multiarm studies were divided into independent studies.